12 December 2024
Latham & Watkins Advises on Rocket Pharmaceuticals’ Upsized Public Offering of Common Stock
Advising firms
Deal team
4 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Nathan Ajiashvili Lead | Latham & Watkins LLP | Partner | capital markets | New York |
| Jie Lin Nai | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Isabelle Sawhney | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Rachel Moore | Latham & Watkins LLP | Associate | capital markets | Not stated |
1 more lawyer on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 165m (US$165 million)
- What the figure measures
- Issue size
- Client
- Not stated
- Counterparties
- Rocket Pharmaceuticals, Inc. (Issuer)